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Abstract 
We present an unusual case of a metastatic mantle cell lymphoma (MCL) to the pituitary 
gland. The patient had a known history of MCL for which she previously received chemother-
apy. She presented with new-onset diplopia and confusion, and reported a history of pro-
gressive vision blurriness associated with headache, nausea, and vomiting. MRI of the brain 
showed an enhancing lesion within the sella turcica involving the cavernous sinuses bilateral-
ly, extending into Meckel’s cave on the left, and abutting the optic nerves bilaterally. Follow-
ing surgical excision, histopathology revealed the tumor to be a MCL. Metastatic pituitary 
tumors are rare and have been estimated to make up 1% of tumors discovered in the sellar 
region. The two most common secondary metastatic lesions to the sella are breast and lung 
carcinoma followed by prostate, renal cell, and gastrointestinal carcinoma. Metastatic lym-
phoma to the pituitary gland is especially rare and is estimated to constitute 0.5% of all met-
astatic tumors to the sella turcica. To our knowledge, this is the first reported case of MCL 
metastasizing to the pituitary gland. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Mantle cell lymphoma (MCL) is a type of B-cell lymphoma, representing approximately 
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expression and the t(11;14) translocation. In addition, it demonstrates CD5, CD19, and CD20 
positivity along with CD10 and CD23 negativity [1]. 
The incidence of central nervous system (CNS) involvement in cases of MCL ranges from 
4 to 26% [2]. It has been known to metastasize to the leptomeninges and brain parenchyma 
[3], with leptomeningeal or cerebrospinal fluid (CSF) involvement being most common [2]. 
Clinical manifestations have been known to include pain, numbness, cranial nerve palsy, 
hearing loss, headache, gait instability, paresthesia, confusion, ocular disturbances, and men-
tal status changes [4–6]. 
Although cases of CNS involvement have been reported, to date there have been no re-
ported cases of MCL metastasizing to the sella turcica, parasellar region, or pituitary gland. A 
total of 1% of tumors in the region of the pituitary are metastases, most commonly present-
ing with diabetes insipidus and anterior pituitary dysfunction [4, 7]. The two most common 
cancers that metastasize to this region are breast cancer at 40% and lung cancer at 33%. In 
addition, cases of metastases of renal cell, prostate, gastrointestinal, thyroid, pancreatic, and 
melanoma have also occurred [4]. Rare cases of lymphoma metastasizing to the pituitary 
have also been reported; however, there have been no reported cases of specifically MCL 
metastasizing to this region [7–9]. To our knowledge, this is the first reported case of a MCL 
metastasis to the pituitary gland. 
Case Report 
Our patient is a 70-year-old female who presented with new-onset diplopia and confu-
sion. She reported a history of progressive vision blurriness for 2 months associated with 
headache, nausea, and vomiting. The patient had a known history of MCL for which she pre-
viously received chemotherapy. On physical exam, she was intact except for a left sixth cra-
nial nerve palsy. Her laboratory values were all normal with the exception of her TSH which 
was low. 
Magnetic resonance imaging (MRI) revealed an aggressive appearing lesion within the 
sella turcica involving the cavernous sinuses bilaterally (fig. 1a). On the left side, the tumor 
extended inferiorly into Meckel’s cave. The tumor encased the left posterior communicating 
artery at its origin, and partially encased the right posterior communicating artery. Superior-
ly, the suprasellar extension of the tumor did not involve the optic chiasm, but was abutting 
the optic nerves (fig. 1b, c). 
Given the patient’s neurologic deficit, as well as the findings on the MRI, an endoscopic 
transphenoidal resection of the lesion was performed. Intraoperative neuronavigation was 
utilized to confirm the location of the carotid arteries and optic nerves. Upon opening of the 
sella dura mater, a firm yellow lesion was encountered. An excisional biopsy was performed 
with debulking of the tumor. An initial frozen section revealed lymphoma. 
Histopathological examination revealed the tumor to be a MCL. Microscopy of the pitui-
tary mass showed atypical lymphocytes in diffuse sheets infiltrating into the pituitary gland 
(fig. 2a). The atypical lymphocytes were small with scant cytoplasm and irregular hyper-
chromatic nuclei with irregular nuclear contours. These lymphocytes were found to displace 
nests of pituitary cells. The tumor cells stained positive for the immunohistochemical stain 
CD20, demonstrating that the tumor cells were a clonal proliferation of B cells (fig. 2b). Flow 
cytometry revealed a surface lambda clonal B-cell population expressing CD19 and CD20. 
Taken together with the patient’s known history of MCL, these findings were consistent with 
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The patient did well following surgery and did not experience any new neurological def-
icit. Upon receiving the pathology, the patient was started on high-dose steroid therapy and 
her visual acuity and fields continued to improve on follow-up serial ophthalmological ex-
ams. Follow-up MRI of the brain was obtained demonstrating decreased size of the patient’s 
pituitary tumor at both 3 and 6 months (fig. 3). 
Discussion 
Metastatic pituitary tumors are rare and have been estimated to make up 1% of tumors 
discovered in the sella region [4]. The two most common secondary metastatic lesions to the 
sella are breast and lung carcinoma followed by prostate, renal cell, and gastrointestinal 
carcinoma [4]. Metastasis to the pituitary gland associated with lymphoma is rare compared 
with solid organ cancers, and is estimated to constitute a total of 0.5% of cases in the sella 
turcica [10]. The sella is a rare location for secondary metastasis. Metastasis to the pituitary 
and sellar region occurs hematogenously via the hypophyseal portal system that supplies 
the anterior pituitary. The posterior lobe of the pituitary is then affected by contiguous 
spread from the anterior pituitary [4]. 
The common presenting symptoms of metastatic sellar and parasellar lesions are simi-
lar to those of primary pituitary adenomas and include headaches, visual field deficits, crani-
al nerve palsies, and endocrine abnormalities such as diabetes insipidus [7]. Our patient 
presented with headaches and blurry vision. Moreover, on detailed neurologic examination, 
she was found to have a left sixth cranial nerve palsy. MRI of the brain revealed an aggres-
sive lesion in the region of the pituitary gland involving the cavernous sinuses bilaterally and 
abutting the optic chiasm superiorly. The patient also had a right adrenal mass on CT abdo-
men. Because of the patient’s established history of MCL, the differential diagnosis included 
pituitary macroadenoma and secondary metastatic MCL to the sella turcica. With cortico-
steroid treatment, the patient noticed improvement in her visual symptoms. 
Given her clinical response to steroids, we were suspicious that it was a secondary MCL 
lesion that metastasized to the pituitary. An endoscopic endonasal transsphenoidal ap-
proach to the pituitary lesion was performed, which revealed a firm yellow lesion. Histologi-
cal examination demonstrated MCL with diffuse sheets of atypical lymphocytes infiltrating 
the pituitary gland. Immunohistochemical stains were diffusely positive for CD5 and CD20. 
Ki-67 showed an average nuclear proliferation index of 20%. Corresponding flow cytometry 
revealed a surface lambda clonal B-cell population expressing CD19, CD20, and co-
expressing CD5 with heterogeneous expression of CD23. The final diagnosis was MCL. Anal-
ysis of CSF at the time of surgery showed a total white cell count of 297, lactate dehydrogen-
ase of 27 and malignant cells seen on CSF cytology. 
MCL is a subtype of B-cell lymphoma that accounts for 4–6% of all lymphomas and is 
genetically characterized by the t(11;14)(q13; q32) translocation with overexpression of 
cyclin D1 [1, 11, 12]. This particular subtype follows an aggressive course and patients are 
generally at an advanced stage with widespread metastatic lesions to the bone marrow, 
blood, and gastrointestinal system upon diagnosis [5]. Median age at diagnosis is the fifth to 
sixth decades of life and survival of patients is estimated at 3–4 years [2]. CNS involvement is 
rare and is an independent poor prognostic factor. It can include leptomeningeal disease 
(positive CSF cytology with normal neuroimaging), combined intraparenchymal and lep-
tomeningeal disease, and very rarely intraparenchymal disease without evidence of lep-
tomeningeal involvement (negative CSF cytology) [2, 5]. It has been estimated that CNS in-
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A literature search revealed four case reports with intraparenchymal CNS involvement 
associated with MCL. MCL was discovered in the spinal epidural space in two of these re-
ports, along the optic nerves in one report, and in the occipital-parietal lobe in the last case 
[2, 11, 13, 14]. To our knowledge, we report the first case of a secondary MCL presenting as a 
pituitary tumor. 
CNS involvement is usually a late presenting event and often seen in association with 
systemic relapse. The median time from diagnosis of MCL to CNS involvement was 25 
months in one case series [6]. Two other publications delineated several risk factors for de-
veloping CNS disease with MCL, including blastoid morphology, elevated serum LDH, and a 
high Ki-67 tumor proliferation index [3, 5]. 
The literature regarding the appropriate management of CNS disease in MCL is limited 
to a few case series [5, 6, 15]. Systemic blastoid MCL without CNS disease is treated with a 
variety of different chemotherapy regimens depending on a patient’s specific profile. The 
most commonly used regimens are cyclophosphamide, doxorubicin, vincristine and predni-
sone (CHOP) or hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexame-
thasone (hyper-CVAD). Once CNS disease is diagnosed, high-dose methotrexate and/or cy-
tarabine is initiated in combination with the patient’s existing regimen [5, 15]. Additionally, 
intrathecal therapy consisting of methotrexate, cytarabine and steroid therapy is initiated 
concurrently [5, 15]. The investigators from the European Mantle Cell Lymphoma Network 
showed that CNS involvement is an independent poor prognostic factor. They found that 
upon diagnosis of CNS disease, whether leptomeningeal or intraparenchymal involvement, 
there was a median survival of 3.7 months [5]. 
MCL is a rare form of non-Hodgkin’s lymphoma. The blastoid variant of MCL is associat-
ed with CNS involvement in the later stages of the disease and carries a poor prognosis. We 
reported the first case of a metastatic MCL lesion to the pituitary gland. Transphenoidal re-
section of the tumor relieved our patient’s neurological symptoms and provided a diagnosis. 
There are several trials underway that are investigating newer chemotherapeutic regimens 
to modulate disease progression. 
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Fig. 1. Axial MRI (a) of the brain demonstrates an enhancing lesion in the sella turcica and suprasellar 
space with extension to the left side of the sella and along the tentorium. Coronal (b) and sagittal (c) Gd-
enhanced T1-weighted images demonstrate the lesion extending into the suprasellar space abutting the 
optic chiasm. The mass extends into the cavernous sinuses bilaterally with encasement of the bilateral 
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Fig. 2. Photomicrographs of tumor sections with H&E staining (a) and immunohistochemical staining 
with CD20 (b). a Monotonous lymphoid cells, which have irregular hyperchromatic nuclei with irregular 
nuclear contours, displace nests of pituitary cells. b The tumor cells stained positive for immunohisto-
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Fig. 3. Follow-up axial and coronal MR imaging at 3 months (a, b) and 6 months (c, d) post-surgery, chem-
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